Rationales and choices for the treatment of patients with NYHA class II heart failure

References

• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–e360.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6:606–619.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240–e319.
   PubMed Web of Science ®Google Scholar
• Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–259.
   PubMed Web of Science ®Google Scholar
• Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996;94:2800–2806.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
   PubMed Web of Science ®Google Scholar
• MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007.
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301:1439–1450.
   PubMed Web of Science ®Google Scholar
• Komajda M, Lutiger B, Madeira H, et al. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). Eur J Heart Fail. 2004;6:467–475.
   PubMed Web of Science ®Google Scholar
• SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.
   PubMed Web of Science ®Google Scholar
• Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004;110:2618–2626.
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.
   PubMed Web of Science ®Google Scholar
• Zareba W, Klein H, Cygankiewicz I, et al. Effectiveness of cardiac resynchronization therapy by QRS morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011;123:1061–1072.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;68:1476–1488.
   PubMed Web of Science ®Google Scholar
• Goldman L, Hashimoto B, Cook EF, et al. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation. 1981;64:1227–1234.
   PubMed Web of Science ®Google Scholar
• Madsen BK, Hansen JF, Stokholm KH, et al. Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms. Eur Heart J. 1994;15:303–310.
   PubMed Web of Science ®Google Scholar
• Ahmed A, Aronow WS, Fleg JL. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J. 2006;151:444–450.
   PubMed Web of Science ®Google Scholar
• Santos AB, Kraigher-Krainer E, Bello N, et al. Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. Eur Heart J. 2014;35:42–47.
   PubMed Web of Science ®Google Scholar
• Spoladore R, Fragasso G, Montanaro C, et al. NYHA Class II subgrouping: correlation with left ventricular dysfunction questionnaire (LVD-36) and ejection fraction. Minerva Cardioangiol. 2010;58:441–448.
   PubMed Web of Science ®Google Scholar
• Ahmed A. A propensity matched study of New York Heart Association class and natural history end points in heart failure. Am J Cardiol. 2007;99:549–553.
   PubMed Web of Science ®Google Scholar
• Mangla A, Kane J, Beaty E, et al. Comparison of predictors of heart failure-related hospitalization or death in patients with versus without preserved left ventricular ejection fraction. Am J Cardiol. 2013;112:1907–1912.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Anker SD, Anand I, et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation. 2007;116:392–398.
   PubMed Web of Science ®Google Scholar
• Machado M, Falcão LM, Ravara L. Sudden death prevention in heart failure. Rev Port Cardiol. 2006;25:727–762.
   PubMedGoogle Scholar
• Böhm M, Tschöpe C, Wirtz JH, et al. Treatment of heart failure in real-world clinical practice: findings from the REFLECT-HF registry in patients with NYHA class II symptoms and a reduced ejection fraction. Clin Cardiol. 2015;38:200–207.
   PubMed Web of Science ®Google Scholar
• Güder G, Störk S, Gelbrich G, et al. Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling. Eur J Heart Fail. 2015;17:442–452.
   PubMed Web of Science ®Google Scholar
• Adams KF Jr., Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209–216.
   PubMed Web of Science ®Google Scholar
• Lee DS, Schull MJ, Alter DA, et al. Early deaths in patients with heart failure discharged from the emergency department: a population-based analysis. Circ Heart Fail. 2010;3:228–235.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;2016(18):891–975.
   Web of Science ®Google Scholar
• Poelzl G, Altenberger J, Pacher R, et al. Dose matters! Optimisation of guideline adherence is associated with lower mortality in stable patients with chronic heart failure. Int J Cardiol. 2014;175:83–89.
   PubMed Web of Science ®Google Scholar
• Mosalpuria K, Agarwal SK, Yaemsiri S, et al. Outpatient management of heart failure in the United States, 2006–2008. Tex Heart Inst J. 2014;41:253–261.
   PubMed Web of Science ®Google Scholar
• Goldberg LR, Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation. 2006;113:2851–2860.
   PubMed Web of Science ®Google Scholar
• Gravely-Witte S, Jurgens CY, Tamim H, et al. Length of delay in seeking medical care by patients with heart failure symptoms and the role of symptom-related factors: a narrative review. Eur J Heart Fail. 2010;12:1122–1129.
   PubMed Web of Science ®Google Scholar
• Patel H, Shafazand M, Schaufelberger M, et al. Reasons for seeking acute care in chronic heart failure. Eur J Heart Fail. 2007;9:702–708.
   PubMed Web of Science ®Google Scholar
• Beygui F, Anguita M, Tebbe U, et al. A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms. Heart Fail Rev. 2015;20:545–552.
   PubMed Web of Science ®Google Scholar
• Braunwald E. Heart failure. JACC Heart Fail. 2013;1:1–20.
   PubMed Web of Science ®Google Scholar
• Kasper DL, Braunwald E, Hauser S, et al. Harrison’s Principles of Internal Medicine, 16th ed. New York, NY: McGraw-Hill, 2005.
   Google Scholar
• Chiong M, Wang ZV, Pedrozo Z, et al. Cardiomyocyte death: mechanisms and translational implications. Cell Death Dis. 2011;2:e244.
   PubMed Web of Science ®Google Scholar
• Cheng S, Vasan RS. Advances in the epidemiology of heart failure and left ventricular remodeling. Circulation. 2011;124:e516–e5199.
   PubMed Web of Science ®Google Scholar
• Brenyo A, Barsheshet A, Kutyifa V, et al. Predictors of spontaneous reverse remodeling in mild heart failure patients with left ventricular dysfunction. Circ Heart Fail. 2014;7:565–572.
   PubMed Web of Science ®Google Scholar
• Godard MP, Whitman SA, Song YH, et al. Skeletal muscle molecular alterations precede whole-muscle dysfunction in NYHA Class II heart failure patients. Clin Interv Aging. 2012;7:489–497.
   PubMed Web of Science ®Google Scholar
• Dubé BP, Agostoni P, Laveneziana P. Exertional dyspnoea in chronic heart failure: the role of the lung and respiratory mechanical factors. Eur Respir Rev. 2016;25:317–332.
   PubMed Web of Science ®Google Scholar
• Ambrosy AP, Khan H, Udelson JE, et al. Changes in dyspnea status during hospitalization and postdischarge health-related quality of life in patients hospitalized for heart failure: findings from the EVEREST trial. Circ Heart Fail. 2016;9. pii: e002458. DOI:10.1161/CIRCHEARTFAILURE.115.002458.
   Web of Science ®Google Scholar
• Madamanchi C, Alhosaini H, Sumida A, et al. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol. 2014;176:611–617.
   PubMed Web of Science ®Google Scholar
• Taylor JA, Christenson RH, Rao K, et al. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J. 2006;152:1071–1076.
   PubMed Web of Science ®Google Scholar
• Silva Marques J, Luz-Rodrigues H, David C, et al. [Biomarkers of functional class in systolic heart failure: the relevance of copeptin]. Rev Port Cardiol. 2012;31:701–710.
   PubMedGoogle Scholar
• Mandavia CH, Aroor AR, Demarco VG, et al. Molecular and metabolic mechanisms of cardiac dysfunction in diabetes. Life Sci. 2013;92:601–608.
   PubMed Web of Science ®Google Scholar
• Uijl E, Roksnoer LC, Hoorn EJ, et al. From ARB to ARNI in cardiovascular control. Curr Hypertens Rep. 2016;18:86.
   PubMed Web of Science ®Google Scholar
• Remme WJ, Riegger G, Hildebrandt P, et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther. 2004;18:57–66.
   PubMed Web of Science ®Google Scholar
• Rogers JK, McMurray JJ, Pocock SJ, et al. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation. 2012;126:2317–2323.
   PubMed Web of Science ®Google Scholar
• Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–533.
   PubMed Web of Science ®Google Scholar
• Abraham WT, Young JB, León AR, et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110:2864–2868.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–1338.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Brown MW, Cannom DS, et al. Multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT): design and clinical protocol. Ann Noninvasive Electrocardiol. 2005;10:34–43.
   PubMed Web of Science ®Google Scholar
• Goldenberg I, Kutyifa V, Klein HU, et al. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med. 2014;370:1694–1701.
   PubMed Web of Science ®Google Scholar
• Veazie PJ, Noyes K, Li Q, et al. Cardiac resynchronization and quality of life in patients with minimally symptomatic heart failure. J Am Coll Cardiol. 2012;60:1940–1944.
   PubMed Web of Science ®Google Scholar
• Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52:1834–1843.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–885.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Zannad F, McMurray JJ, et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) study. J Am Coll Cardiol. 2012;59:1598–1603.
   PubMed Web of Science ®Google Scholar
• Li X, Qi Y, Li Y, et al. Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail. 2013;6:156–165.
   PubMed Web of Science ®Google Scholar
• Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015;36:1831–1838.
   PubMed Web of Science ®Google Scholar
• Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451.
   PubMed Web of Science ®Google Scholar
• Dobre D, Borer JS, Fox K, et al. Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. Eur J Heart Fail. 2014;16:76–85.
   PubMed Web of Science ®Google Scholar
• Habal MV, Liu PP, Austin PC, et al. Association of heart rate at hospital discharge with mortality and hospitalizations in patients with heart failure. Circ Heart Fail. 2014;7:12–20.
   PubMed Web of Science ®Google Scholar
• Borer JS, Böhm M, Ford I, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J. 2012;33:2813–2820.
   PubMed Web of Science ®Google Scholar
• Amgen, Inc. Corlanor (ivabradine) [prescribing information]. Thousand Oaks (CA): Amgen; 2017.
   Google Scholar
• Solomon SD, Claggett B, Packer M, et al. Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM-HF trial. JACC Heart Fail. 2016;4:816–822.
   PubMed Web of Science ®Google Scholar
• Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36:1990–1997.
   PubMed Web of Science ®Google Scholar
• Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54–61.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Corp. Entresto (sacubitril and valsartan) [prescribing information]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2015.
   Google Scholar
• Figueroa MS, Peters JI. Congestive heart failure: diagnosis, pathophysiology, therapy, and implications for respiratory care. Respir Care. 2006;51:403–412.
   PubMed Web of Science ®Google Scholar
• Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD investigators. Survival with oral d-sotalol. Lancet. 1996;348:7–12.
   PubMed Web of Science ®Google Scholar
• Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678–2687.
   PubMed Web of Science ®Google Scholar
• Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406–412.
   PubMed Web of Science ®Google Scholar
• Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet. 1994;344:493–498.
   PubMed Web of Science ®Google Scholar
• Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival trial of antiarrhythmic therapy in congestive heart failure. N Engl J Med. 1995;333:77–82.
   PubMed Web of Science ®Google Scholar
• Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999;341:857–865.
   PubMed Web of Science ®Google Scholar
• Kober L, Bloch Thomsen PE, Moller M, et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet. 2000;356:2052–2058.
   PubMed Web of Science ®Google Scholar
• Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009;169:141–149.
   PubMed Web of Science ®Google Scholar
• Heerdink ER, Leufkens HG, Herings RM, et al. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med. 1998;158:1108–1112.
   PubMed Web of Science ®Google Scholar
• Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ. 2005;330:1370.
   PubMed Web of Science ®Google Scholar
• Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical and medical group survival in patients with left main coronary artery disease. Long-term CASS experience. Circulation. 1995;91:2325–2334.
   PubMed Web of Science ®Google Scholar
• Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237.
   PubMed Web of Science ®Google Scholar
• Kober L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221–1230.
   PubMed Web of Science ®Google Scholar
• Linde C, Gold MR, Abraham WT, et al. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J. 2013;34:2592–2599.
   PubMed Web of Science ®Google Scholar
• Adabag S, Roukoz H, Anand IS, et al. Cardiac resynchronization therapy in patients with minimal heart failure: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58:935–941.
   PubMed Web of Science ®Google Scholar
• Tu R, Zhong G, Zeng Z, et al. Cardiac resynchronization therapy in patients with mild heart failure: a systematic review and meta-analysis of randomized controlled trials. Cardiovasc Drugs Ther. 2011;25:331–340.
   PubMed Web of Science ®Google Scholar
• Philipson H, Ekman I, Forslund HB, et al. Salt and fluid restriction is effective in patients with chronic heart failure. Eur J Heart Fail. 2013;15:1304–1310.
   PubMed Web of Science ®Google Scholar
• Gielerak G, Piotrowicz E, Krzesinski P, et al. The effects of cardiac rehabilitation on haemodynamic parameters measured by impedance cardiography in patients with heart failure. Kardiol Pol. 2011;69:309–317.
   PubMed Web of Science ®Google Scholar
• Al-Gobari M, El Khatib C, Pillon F, et al. Beta-blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2013;13:52.
   PubMed Web of Science ®Google Scholar
• Bapoje SR, Bahia A, Hokanson JE, et al. Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail. 2013;6:166–173.
   PubMed Web of Science ®Google Scholar
• Riles EM, Jain AV, Fendrick AM. Medication adherence and heart failure. Curr Cardiol Rep. 2014;16:458.
   PubMed Web of Science ®Google Scholar
• Wu JR, Moser DK, Chung ML, et al. Objectively measured, but not self-reported, medication adherence independently predicts event-free survival in patients with heart failure. J Card Fail. 2008;14:203–210.
   PubMed Web of Science ®Google Scholar
• Ghali JK, Kadakia S, Cooper R, et al. Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch Intern Med. 1988;148:2013–2016.
   PubMedGoogle Scholar
• Michalsen A, König G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart. 1998;80:437–441.
   PubMed Web of Science ®Google Scholar
• Ni H, Nauman D, Burgess D, et al. Factors influencing knowledge of and adherence to self-care among patients with heart failure. Arch Intern Med. 1999;159:1613–1619.
   PubMed Web of Science ®Google Scholar
• Rich MW, Gray DB, Beckham V, et al. Effect of a multidisciplinary intervention on medication compliance in elderly patients with congestive heart failure. Am J Med. 1996;101:270–276.
   PubMed Web of Science ®Google Scholar
• Oosterom-Calo R, van Ballegooijen AJ, Terwee CB, et al. Determinants of adherence to heart failure medication: a systematic literature review. Heart Fail Rev. 2013;18:409–427.
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Stevenson LW, Walden JA, et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol. 1997;30:725–732.
   PubMed Web of Science ®Google Scholar
• Hanumanthu S, Butler J, Chomsky D, et al. Effect of a heart failure program on hospitalization frequency and exercise tolerance. Circulation. 1997;96:2842–2848.
   PubMed Web of Science ®Google Scholar